We read with great interest the article of Carvalho et al. reporting the impact of single-nucleotide polymorphisms (SNPs) in genes involved in the IL-23/Th17 pathway on the outcome of SCT. Their comprehensive multivariate analyses showed significant associations between SNPs in IL-17 and the IL-23 receptor (IL-23R) genes and infectious complications, the occurrence of acute GVHD, disease relapse, and overall survival of SCT recipients. 1 Genetic association studies have helped enhance our understanding of the pathogenesis of SCT complications and transplant immunology. 2, 3 However, establishing the clinical utility of these SNPs using patient and donor material has proven challenging mainly because of the difficulties encountered in performing SNP analysis, such as the lack of reproducibility, inadequate sample sizes, publication bias and the context (genetic background, type of transplantation and so on). 4 We would also like to highlight two additional issues concerning SNP analysis, namely, the limitations of statistical analysis and the biological plausibility of genetic associations.
It is vital to appreciate the limitations of the statistical tools used for the analysis when exploring the impact of multiple SNPs among heterogeneous cohorts of limited sample size so as not to claim associations or overestimate the impact when there are none. In their multivariate analysis of acute GVHD, the authors used only those factors that were found to yield a P-value p0.15 in univariate analysis-4 variables in total, namely, phase of disease, IL-17F rs763780 in donor and recipient, and IL-17A rs8193036 in the recipient. However, how is one to interpret the finding of such high hazard ratios for three associations when the event rate-acute GVHD-affected only 12 (6%) of the 201 patients? A fitted regression model is only likely to be reliable when the number of predictors (or candidate predictors if using variable selection) is less than m/10 or even m/20, where m is the 'limiting sample size'. In the case of survival-time analyses, the 'limiting sample size' equals the number of failures, for example, occurrence of GVHD, death or relapse in this case. 5 The limiting sample size for analysing the acute GVHD end point appears to be 12; hence, any multivariable analysis taking two or more predictors into account is unlikely to prove reliable and any hazard ratios that are high must be viewed with suspicion. The same applies to the end point of CMV infection, as 20 observed events does not allow proper multivariable analysis starting with five predictors. Given the authors' own comment that the low event rate precludes proper appreciation of their findings, perhaps it would have been better to omit their multivariate analysis altogether, as it neither weakens nor strengthens their message that SNPs in the IL-23/Th17 pathway might be prognostic factors for the SCT outcome.
The chance that significant associations, even with impressive low P-values, are really true depends largely on whether the association is biologically plausible. Following Bayesian approaches, genetic associations have a higher positive predictive value when the pre-study probability of a real association is high. 6 The pre-study probability relates, among other things, to the biological plausibility, as the positive or negative genetic association can be explained within the prevailing pathophysiological framework. For example, the role of the Nod-like receptor 2 (NOD2) in mucosal immunity and inflammation has been firmly established, and, correspondingly, SNPs in NOD2 that result in a change in biological function of the receptor are associated with uncontrolled inflammatory complications, including acute GVHD. 2 In the present study, SNPs in immune genes of the patients were related to the occurrence of acute GVHD, disease relapse and infectious complications. However, IL-17A, IL-17F and IL-23R are almost exclusively expressed in haematopoietic cells, 7, 8 and predominantly involved in lymphocytic responses and, in case of myeloablative conditioning, the whole haematopoietic compartment of patients is heavily depleted, especially after TBI. Therefore, and because disease relapse and GVHD are related to allo-reactive T-cell responses and viral infections to reconstitution of donor immune cells, the presence of IL-17 and IL-23R polymorphisms in patient genes cannot easily explain differences in clinical outcomes of SCT, except when these genes have a role before the start of conditioning or in the brief period of patient-donor chimerism. The authors' claim that genetic variants in the IL-23/Th17 pathway in patients are associated with the outcome of SCT would have been strengthened had they proposed a biological explanation for this association. Clearly, more experimental and clinical data are needed before any impact of alterations in the IL-23/Th17 pathway of patients on the outcome of SCT can be assigned.
We acknowledge fully the difficulties encountered in SNP analysis, but we need to acknowledge the limitations of statistical analysis and fully accept the need to test it in a biologically plausible framework if we are really to detect clinically important SNP associations in the setting of SCT.
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